Floatz Rating
BB67/100
Confidence
Indicative
Sponsor
Fudan University
Modality
monoclonal_antibody
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
73High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07318389CT.gov ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer | — | Not Yet Recruiting | — | — | — |
NCT07621497CT.gov FOLFOX8 Versus mFOLFOX6 With Bevacizumab or Cetuximab for First-Line Unresectable Metastatic Colorectal Cancer (Phase II) | — | Not Yet Recruiting | — | — | — |
NCT07515963CT.gov FULIRI Plus Targeted Therapy for First-line Conversion Therapy of Colorectal Cancer Liver Metastases. | — | Not Yet Recruiting | — | — | — |
NCT07595276CT.gov Comparing Efficacy and Safety of Enlituo® Versus Erbitux® Plus FOLFOX in Locally Advanced/Metastatic Colorectal Cancer With RAS/BRAF Wild-type and MSS/pMMR Status. | — | Not Yet Recruiting | — | — | — |
NCT07604909CT.gov A Phase II Randomized Trial of Serplulimab With Second-Line Chemo/Targeted Therapy for Early Relapse Colorectal Cancer After Adjuvant Chemotherapy | — | Recruiting | — | — | — |
NCT07551778CT.gov Allogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced Solid Tumors | — | Not Yet Recruiting | — | — | — |
NCT07581912CT.gov Neoadjuvant Treatment of Fulzerasib Plus Cetuximab N01 in KRAS G12C Mutated Locally Advanced Colorectal Cancer With or Without Resectable Metastases | — | Recruiting | — | — | — |
NCT07411599CT.gov Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out (KO) Therapy For Colorectal Cancer-Related Peritoneal Carcinomatosis: A Phase 1/2 Trial ("Chip-CRC Trial") | — | Recruiting | — | — | — |
NCT07094893CT.gov Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG High Status | — | Not Yet Recruiting | — | — | — |
NCT07503639CT.gov Umbrella Trial of Neoadjuvant Therapy for Locally Advanced Colorectal Cancer | — | Not Yet Recruiting | — | — | — |
Show 291 more trialsShow fewer
NCT07474727CT.gov A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer | — | Not Yet Recruiting | — | — | — |
NCT07381764CT.gov ROMANCE: "Irinotecan Plus Cetuximab Rechallenge Versus Trifluridine/Tipiracil Plus Bevacizumab in Molecularly Selected Metastatic Colorectal Cancer" | — | Not Yet Recruiting | — | — | — |
NCT07446270CT.gov Efficacy of Tunlametinib in Combination With Anti-EGFR Monoclonal Antibody in Patients With RAS-Mutated Advanced Gastrointestinal Malignancies | — | Not Yet Recruiting | — | — | — |
NCT07506109CT.gov A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer | — | Recruiting | — | — | — |
NCT07397338CT.gov Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors | — | Recruiting | — | — | — |
NCT07353268CT.gov Phase Ib/II Study of QL1706 + Fruquintinib + SCRT vs. Standard Third-Line Therapy in Unresectable Liver-Metastatic pMMR/MSS Colorectal Cancer: Safety, Tolerability, and Efficacy. | — | Not Yet Recruiting | — | — | — |
NCT07349537CT.gov Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors | — | Recruiting | — | — | — |
NCT07318805CT.gov A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors | — | Recruiting | — | — | — |
NCT07223047CT.gov A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies | — | Recruiting | — | — | — |
NCT07300150CT.gov A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT07216105CT.gov FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT07559760CT.gov New Second-Line Combo Therapy for MSS Metastatic Colorectal Cancer | — | Recruiting | — | — | — |
NCT07389265CT.gov Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer | — | Recruiting | — | — | — |
NCT07059338CT.gov Dual EGFR/HER2 Blockade Combined With Irinotecan for the Treatment of HER2-Positive Metastatic Colorectal Cancer | — | Not Yet Recruiting | — | — | — |
NCT07309289CT.gov NALIRIFOX Plus Targeted Therapy Versus FOLFOX Plus Targeted Therapy as First-line Treatment for Metastatic Colorectal Cancer | — | Recruiting | — | — | — |
NCT07020221CT.gov A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors | — | Recruiting | — | — | — |
NCT07000305CT.gov A Study of Cetuximabβ Combined With Envolimab and mFOLFOX6 in Subjects With Advanced Colorectal Cancer | — | Not Yet Recruiting | — | — | — |
NCT07204574CT.gov The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI in Advanced or Metastatic Colorectal Cancer | — | Recruiting | — | — | — |
NCT06922383CT.gov A Clinical Study of Arfolitixorin in Patients With mCRC | — | Recruiting | — | — | — |
NCT06917079CT.gov BBO-11818 in Adult Subjects With KRAS Mutant Cancer | — | Recruiting | — | — | — |
NCT06835569CT.gov A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations | — | Recruiting | — | — | — |
NCT06369259CT.gov Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer | — | Recruiting | — | — | — |
NCT06720987CT.gov A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies | — | Recruiting | — | — | — |
NCT06585488CT.gov A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification | — | Terminated | — | — | — |
NCT06358430CT.gov Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD) | — | Recruiting | — | — | — |
NCT06607185CT.gov A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT06599502CT.gov A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD0022 as Monotherapy and in Combination With Anti-cancer Agents in Adult Participants With Tumours Harbouring a KRASG12D Mutation | — | Terminated | — | — | — |
NCT06616259CT.gov First-line Treatment of MCapOX + Cetuximab Vs. MFOLFOX6 + Cetuximab for RAS/BRAF Wild-type, MSS, Unresectable Left-Sided MCRC: a Multicenter, Randomized, Controlled, Phase III Study | — | Not Yet Recruiting | — | — | — |
NCT06586515CT.gov MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors | — | Recruiting | — | — | — |
NCT06412198CT.gov A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations | — | Recruiting | — | — | — |
NCT06279351CT.gov Thalidomide Enhances Clinical Efficacy of Cetuximab Combined With Standard Chemotherapy for Left Colorectal Cancer | — | Recruiting | — | — | — |
NCT06578559CT.gov Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC | — | Active Not Recruiting | — | — | — |
NCT06102902CT.gov Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer | — | Suspended | — | — | — |
NCT06640166CT.gov Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab. | — | Recruiting | — | — | — |
NCT06445062CT.gov Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors | — | Recruiting | — | — | — |
NCT06411600CT.gov Combination Therapy for BRAF-V600E Metastatic CRCm | — | Recruiting | — | — | — |
NCT06207656CT.gov Study to Evaluate the Efficacy and Safety of Cetuximab in Combination with Encorafenib Plus Binimetinib As Induction Treatment in BRAF V600E Mutated MSS Initially Resectable or Potentially Resectable Advanced Colorectal Cancer | — | Recruiting | — | — | — |
NCT06525428CT.gov Standard Systemic Therapy Combined With High/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer | — | Recruiting | — | — | — |
NCT06225622CT.gov Dose Escalation and Expansion Clinical Trial of Irinotecan Liposome Combined With Oxaliplatin and 5-FU/LV Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer | — | Unknown | — | — | — |
NCT07079462CT.gov Comparing 18F-FAPI PET-Guided Abdominal Radiotherapy Combined With Second-Line Standard Therapy and Cadonilimab Versus Second-Line Standard Therapy in Colorectal Cancer With Peritoneal Metastasis | — | Recruiting | — | — | — |
NCT06321081CT.gov ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC | — | Recruiting | — | — | — |
NCT06231017CT.gov Adebrelimab Plus Cetuximab and Chemotherapy for Patients With RAS/BRAF Wild-Type Unresectable Liver Metastases Colorectal Cancer | — | Unknown | — | — | — |
NCT05985954CT.gov Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy | — | Recruiting | — | — | — |
NCT05954871CT.gov Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT06776757CT.gov Sintilimab in Combination with Cetuximab and Chemotherapy As First-line Treatment for RAS/BRAF Wild-type Advanced Colorectal Cancer | — | Recruiting | — | — | — |
NCT06011772CT.gov EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer | — | Active Not Recruiting | — | — | — |
NCT05722327CT.gov Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer | — | Active Not Recruiting | — | — | — |
NCT05959356CT.gov Cetuximab and Envafolimab Plus mFOLFOXIRI as First-line Treatment for RAS/BRAF Wild-type, MSS, Unresectable Left-side Metastatic Colorectal Cancer | — | Recruiting | — | — | — |
NCT05863195CT.gov Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial | — | Recruiting | — | — | — |
NCT05962502CT.gov Cetuximab Plus Irinotecan in Patients With NeoRAS Wild-type Metastatic Colorectal Cancer In Third-line Therapy | — | Recruiting | — | — | — |
NCT05963087CT.gov Cetuximab in Combination With Dabrafenib and Tislelizumab in BRAF Mutated Treatment of Advanced Colorectal Cancer | — | Not Yet Recruiting | — | — | — |
NCT06118047CT.gov Crisaborole Ointment for Skin Toxicity Induced by Cetuximab | — | Unknown | — | — | — |
NCT05948072CT.gov Cetuximab+mFOLFOX6 VS. mFOLFOX6 Alone in RAS/BRAF Wild Type Patients With High-Risk Resectable CRLM | — | Not Yet Recruiting | — | — | — |
NCT05786924CT.gov Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies | — | Recruiting | — | — | — |
NCT05799443CT.gov Efficacy and Safety of SBRT Followed by Tislelizumab Plus Cetuximab and Irinotecan in Patients With Previously Treated RAS Wild-type Advanced Refractory Colorectal Cancer | — | Unknown | — | — | — |
NCT05652894CT.gov A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer | — | Active Not Recruiting | — | — | — |
NCT05743036CT.gov ZN-c3 in Adult Participants With Metastatic Colorectal Cancer | — | Terminated | — | — | — |
NCT05706779CT.gov Encorafenib Plus Cetuximab in a Neoadjuvant Setting in Patients With BRAF Mutation Localised Colon or Upper Rectum Cancer | — | Recruiting | — | — | — |
NCT05775900CT.gov Efficacy and Safety of Triweekly Cetuximab in Combination With Capecitabine as First-line Maintenance Treatment for KRAS/BRAF Wild-type Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT05694936CT.gov Combining Sodium Valproate With Standard-of-care EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibody Treatment in Patients With Metastatic Colorectal Cancer | — | Active Not Recruiting | — | — | — |
NCT05684211CT.gov A Study of Ametumumab in Combination With Anti-PD-1 Monoclonal Antibody and FOLFIRI in Patients With RAS Wild-type Advanced Colorectal Cancer | — | Unknown | — | — | — |
NCT05619172CT.gov A Study of Nanrilkefusp Alfa (SOT101) in Combination With Cetuximab to Evaluate the Efficacy and Safety in Patients With Colorectal Cancer | — | Terminated | — | — | — |
NCT05668585CT.gov A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors | — | Completed | — | — | — |
NCT05358249CT.gov Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation | — | Active Not Recruiting | — | — | — |
NCT05576896CT.gov Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory | — | Terminated | — | — | — |
NCT05725200CT.gov Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer | — | Recruiting | — | — | — |
NCT05155124CT.gov Safety of Cetuximab and Trifluridin Tipiracil as the Third-line Therapy in the RASwt mCRC | — | Unknown | — | — | — |
NCT02826837CT.gov LEAC-102 for Advanced Colorectal Cancer | — | Unknown | — | — | — |
NCT05200442CT.gov A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer | — | Suspended | — | — | — |
NCT05497336CT.gov A Study of IBI351 in Combination With Cetuximab in Subjects With KRAS G12C Mutated Metastatic Colorectal Cancer | — | Unknown | — | — | — |
NCT05167409CT.gov A Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer | — | Active Not Recruiting | — | — | — |
NCT05291156CT.gov CAVE-2 GOIM Study: a Clinical Study of the Combination of Avelumab Plus Cetuximab as Rechallenge Strategy | — | Unknown | — | — | — |
NCT05278351CT.gov Tislelizumab Plus Cetuximab and Irinotecan vs Third-line Standard-of-care in Refractory mCRC | — | Unknown | — | — | — |
NCT05217446CT.gov A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer | — | Active Not Recruiting | — | — | — |
NCT05355701CT.gov A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations. | — | Recruiting | — | — | — |
NCT05395052CT.gov FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors | — | Terminated | — | — | — |
NCT05544812CT.gov A Small-sample, Real-world Study of Sintilimab Plus Bevacizumab/Cetuximab Plus XELOX Regimen for Conversion Therapy in Patients With Advanced Colorectal Cancer | — | Unknown | — | — | — |
NCT05194995CT.gov JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation | — | Active Not Recruiting | — | — | — |
NCT05978349CT.gov PTC Drug Sensitivity Detection to Guide Postoperative Adjuvant of Colorectal Cancer | — | Unknown | — | — | — |
NCT05104567CT.gov A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203) | — | Completed | — | — | — |
NCT04853043CT.gov Cetuximab in Third Line for Mutant APC, TP53 and RAS Patients With Refractory Metastatic Colorectal Cancer | — | Terminated | — | — | — |
NCT02942706CT.gov Cetuximab Maintenance Treatment Versus Continuation After Induction Therapy in mCRC | — | Unknown | — | — | — |
NCT05103020CT.gov Phase II Study Comparing Conversion Rate to Surgery With Hepatic Arterial Infusion Chemotherapy to Systemic Chemotherapy in Patients With Non Resectable Liver-only Colorectal Metastases | — | Unknown | — | — | — |
NCT04929223CT.gov A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC) | — | Recruiting | — | — | — |
NCT04262635CT.gov Cetuximab Plus Capecitabine as Maintenance Treatment in RAS and BRAF wt Metastatic Colorectal Cancer | — | Unknown | — | — | — |
NCT06540261CT.gov The Study of ONO-7913, ONO-4538 and the Standard of Care as First-line Treatment in Patients Colorectal Cancer | — | Active Not Recruiting | — | — | — |
NCT05039177CT.gov A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies | — | Completed | — | — | — |
NCT05004350CT.gov A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer. | — | Completed | — | — | — |
NCT05074966CT.gov The Efficacy and Safety of Modified XELOX(mXELOX) Plus Cetuximab vs FOLFOX Plus Cetuximab in RAS and BRAF WT mCRC Pts | — | Unknown | — | — | — |
NCT05002270CT.gov JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation | — | Completed | — | — | — |
NCT04984369CT.gov The Efficacy of HLX208 (BRAF V600E Inhibitor) With Cetuximab for Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation After First-line Treatment | — | Unknown | — | — | — |
NCT05022030CT.gov First-line mCapOX+Cetuximab vs. mFOLFOX6+Cetuximab for Metastatic Left-sided CRC With Wild-type RAS/BRAF Genes | — | Unknown | — | — | — |
NCT04793958CT.gov Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10) | — | Active Not Recruiting | — | — | — |
NCT04464967CT.gov Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers | — | Withdrawn | — | — | — |
NCT04687631CT.gov Conversion Therapy of RAS/BRAF Wild-Type Colorectal Cancer Patients With Initially Unresectable Liver Metastases | — | Recruiting | — | — | — |
NCT04466254CT.gov Efficacy and Safety Study of Combination of CPGJ602 and Chemotherapy, in First Line, With Wild KRAS/NRAS/BRAF in Metastatic Colorectal Cancer | — | Unknown | — | — | — |
NCT04616183CT.gov LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer | — | Active Not Recruiting | — | — | — |
NCT04668976CT.gov A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma | — | Unknown | — | — | — |
NCT04616196CT.gov Study of NKTR 255 in Combination With Cetuximab in Solid Tumors | — | Completed | — | — | — |
NCT04587128CT.gov Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC | — | Active Not Recruiting | — | — | — |
NCT04585035CT.gov Study to Evaluate D-1553 in Subjects With Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT04525326CT.gov Conversion Therapy of RAS/BRAF Wild-Type Right-sided Colon Cancer Patients With Initially Unresectable Liver Metastases | — | Unknown | — | — | — |
NCT04509635CT.gov Cetuximab Re-challenge for Colorectal Cancer Liver Metastasis | — | Unknown | — | — | — |
NCT04449874CT.gov A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation | — | Active Not Recruiting | — | — | — |
NCT04495621CT.gov MEN1611 With Cetuximab in Metastatic Colorectal Cancer (C-PRECISE-01) | — | Completed | — | — | — |
NCT04513951CT.gov AVELUMAB and CETUXIMAB and mFOLFOXIRI as Initial Therapy for Unresectable Metastatic Colorectal Cancer Patients | — | Completed | — | — | — |
NCT04117945CT.gov Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer | — | Active Not Recruiting | — | — | — |
NCT04126655CT.gov Modelle 001, TS-inhibition in Colorectal Liver Metastases Comparing Arfolitixorin and Calciumfolinate | — | Unknown | — | — | — |
NCT03774680CT.gov Targeted Polymeric Nanoparticles Loaded With Cetuximab and Decorated With Somatostatin Analogue to Colon Cancer | — | Unknown | — | — | — |
NCT04224415CT.gov Re-challenge of Anti-EGFR for Patients With RAS/BRAF Wild-type Metastatic CRC | — | Completed | — | — | — |
NCT04189055CT.gov Cetuximab as Salvage Therapy in Patients With Neo Wild-type RAS/RAF Metastatic Colorectal Cancer With Liver Metastases. | — | Unknown | — | — | — |
NCT04241731CT.gov A Study of Cetuximab Plus Raltitrexed for Maintenance Treatment in Advanced Colorectal Cancer | — | Unknown | — | — | — |
NCT04165031CT.gov A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation | — | Terminated | — | — | — |
NCT04833036CT.gov c-CetuIRI Versus Ersecond-line Irinotecan s-IRI-CetuIRI | — | Unknown | — | — | — |
NCT04008030CT.gov A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) | — | Active Not Recruiting | — | — | — |
NCT03366155CT.gov Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver | — | Completed | — | — | — |
NCT04017650CT.gov Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer | — | Active Not Recruiting | — | — | — |
NCT03688230CT.gov Study of Abituzumab in Combination With Cetuximab and FOLFIRI in Patients With Metastatic Colorectal Cancer. | — | Withdrawn | — | — | — |
NCT03750786CT.gov A Study to Compare the Efficacy of Arfolitixorin Versus Leucovorin in Combination With 5 Fluorouracil, Oxaliplatin, and Bevacizumab in Patients With Advanced Colorectal Cancer | — | Completed | — | — | — |
NCT03693807CT.gov A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma | — | Completed | — | — | — |
NCT03727763CT.gov Cetuximab and Vemurafenib Plus FOLFIRI for BRAF V600E Mutated Advanced Colorectal Cancer (IMPROVEMENT) | — | Unknown | — | — | — |
NCT03608046CT.gov Avelumab Combined With Cetuximab and Irinotecan for Treatment Refractory Metastatic Colorectal Microsatellite Stable Cancer | — | Unknown | — | — | — |
NCT04561336CT.gov Avelumab Plus Cetuximab in Pre-treated RAS Wild Type Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT03169777CT.gov QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC | — | Withdrawn | — | — | — |
NCT03491709CT.gov A Preliminary Clinical Study on the Pharmacokinetics and Safety of CDP1 in Patients With Advanced CRC or HNSCC | — | Unknown | — | — | — |
NCT05540951CT.gov VIC Regimen Versus Bevacizumab Plus Chemotherapy as First-Line Treatment for BRAF V600E-Mutated Advanced Colorectal Cancer | — | Unknown | — | — | — |
NCT03457896CT.gov Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status | — | Unknown | — | — | — |
NCT03186326CT.gov Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer | — | Completed | — | — | — |
NCT03493048CT.gov Cetuximab Plus FOLFOXIRI vs Cetuximab Plus FOLFOX For CRCLM | — | Active Not Recruiting | — | — | — |
NCT03446157CT.gov Palbociclib and Cetuximab in Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT03391934CT.gov Comparing Efficacy and Safety of Cetuximab (CinnaGen) Versus Erbitux® (Merck) in Metastatic Colorectal Cancer | — | Unknown | — | — | — |
NCT03319459CT.gov FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors | — | Completed | — | — | — |
NCT03401957CT.gov The Emergence of RAS Mutations in Metastatic Colorectal Cancer Patients Receiving Cetuximab Treatment | — | Unknown | — | — | — |
NCT03290937CT.gov Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT03356158CT.gov A Study of Recombinant Anti-EGFR Monoclonal Antibody in Patients With Metastatic Colorectal Cancer | — | Unknown | — | — | — |
NCT02630420CT.gov Cetuximab and Savolitinib Treatment of Ras Wild-Type Colorectal Cancer | — | Withdrawn | — | — | — |
NCT03017807CT.gov Safety and Pharmacokinetics of Recombinant Anti-EGFr Antibody in Patients With Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT04034459CT.gov FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRC | — | Unknown | — | — | — |
NCT02953782CT.gov Study of Magrolimab (Hu5F9-G4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer | — | Completed | — | — | — |
NCT02978313CT.gov Cetuximab Monotherapy Maintenance Treatment in mCRC | — | Unknown | — | — | — |
NCT02857270CT.gov A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer | — | Completed | — | — | — |
NCT02713373CT.gov Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery | — | Completed | — | — | — |
NCT03031444CT.gov Perioperative Chemotherapy Plus Cetuximab Versus Chemotherapy Alone for High Risk Resectable Colorectal Liver Metastasis | — | Completed | — | — | — |
NCT02515734CT.gov A Study of FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab | — | Unknown | — | — | — |
NCT02573220CT.gov Irinotecan Hydrochloride With FOLFIRI and Cetuximab as First-Line Therapy in Treating Patients With RAS Wild-Type Colorectal Cancer | — | Withdrawn | — | — | — |
NCT02291289CT.gov A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) | — | Completed | — | — | — |
NCT02934529CT.gov Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab | — | Completed | — | — | — |
NCT02292758CT.gov Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery | — | Completed | — | — | — |
NCT02278133CT.gov Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations | — | Completed | — | — | — |
NCT02164916CT.gov S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT02318901CT.gov Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer | — | Terminated | — | — | — |
NCT02296203CT.gov Cetuximab Rechallenge in Irinotecan-pretreated mCRC, KRAS, NRAS and BRAF Wild-type Treated in 1st Line With Anti-EGFR Therapy (CRICKET). | — | Unknown | — | — | — |
NCT02205398CT.gov Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy | — | Terminated | — | — | — |
NCT01871311CT.gov A Phase I Study of Nilontinib and Cetuximab in Patients With Solid Tumors | — | Terminated | — | — | — |
NCT02117466CT.gov Image Guided Treatment Optimization With Cetuximab for Patients With Metastatic Colorectal Cancer | — | Terminated | — | — | — |
NCT02110082CT.gov Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer | — | Completed | — | — | — |
NCT01858662CT.gov Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Treatment Combining Cetuximab With FOLFOX or FOLFIRI in RAS and B-RAF WT Tumors | — | Terminated | — | — | — |
NCT02404935CT.gov Treatment After Irinotecan-based Frontline Therapy: Maintenance With Erbitux (in Patients wtRAS mCRC) | — | Completed | — | — | — |
NCT01925274CT.gov A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer | — | Terminated | — | — | — |
NCT01960023CT.gov Safety and Efficacy Study of Neratinib and Cetuximab to Treat Patients With Quadruple Wild-Type Metastatic Colorectal Cancer | — | Withdrawn | — | — | — |
NCT02071069CT.gov Efficacy and Tolerance of Maintenance Therapy in Patients With Incurable Advanced Colorectal Cancer | — | Unknown | — | — | — |
NCT01834014CT.gov Exploratory Study in Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases | — | Completed | — | — | — |
NCT01832467CT.gov Cetuximab Rechallenge Study | — | Completed | — | — | — |
NCT01802645CT.gov Cetuximab/FOLFIRI With or Without Oxaliplatin and FOLFOXIRI With or Without Bevacizumab in Neoadjuvant Treatment of Non-resectable Colorectal Liver Metastases | — | Unknown | — | — | — |
NCT01787500CT.gov Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery | — | Completed | — | — | — |
NCT01719380CT.gov Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT01718808CT.gov Cetuximab for Elderly Patients With mCRC | — | Terminated | — | — | — |
NCT02994888CT.gov PROSPECT-C: A Study of Biomarkers of Response or Resistance to Anti-EGFR Therapies in Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT01652482CT.gov Safety and Efficacy Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI as Second Line Therapy in Participants With KRAS Wild-Type Metastatic Colorectal Cancer (mCRC) | — | Completed | — | — | — |
NCT01919879CT.gov Dual Targeting of EGFR With Cetuximab and Afatinib to Treat Refractory wtKRAS Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT01631539CT.gov Chemoembolisation With CPT11 Loaded DC Bead With Cetuximab and 5FU/LV in First Line in Patients With KRAS Wildtype mCRC | — | Withdrawn | — | — | — |
NCT01867697CT.gov Nordic 8 - A Phase II Trial | — | Completed | — | — | — |
NCT01776307CT.gov A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer | — | Completed | — | — | — |
NCT01451632CT.gov A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers | — | Completed | — | — | — |
NCT01338558CT.gov A Study of Avastin (Bevacizumab) in Combination With mFOLFOX6 in Treatment-Naïve Patients With Metastatic Colorectal Cancer With or Without K-RAS Mutations, and Comparison to Cetuximab | — | Withdrawn | — | — | — |
NCT01326000CT.gov A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT01309126CT.gov Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer | — | Terminated | — | — | — |
NCT01442935CT.gov Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases | — | Completed | — | — | — |
NCT01079780CT.gov Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy | — | Completed | — | — | — |
NCT01287130CT.gov AZD6244 With Cetuximab for Solid Tumors and Colorectal Cancer | — | Completed | — | — | — |
NCT01276379CT.gov Study Evaluating Biomarkers in Patients With Colorectal Cancer and Native KRAS Treated With Chemotherapy + Cetuximab | — | Completed | — | — | — |
NCT01251536CT.gov Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer | — | Completed | — | — | — |
NCT01442649CT.gov Efficacy of Chemotherapy, Associated to Either Cetuximab or Bevacizumab, in KRAS Wild-type Metastatic Colorectal Cancer Patients With Progressive Disease After Receiving First-line Treatment With Bevacizumab | — | Completed | — | — | — |
NCT01281761CT.gov Simvastatin + Cetuximab/Irinotecan in K-ras Mutant Colorectal Cancer (CRC) | — | Completed | — | — | — |
NCT01228734CT.gov A Trial to Compare Oxaliplatin, Folinic Acid (FA) and 5-Fluorouracil (5FU) Combination Chemotherapy (FOLFOX-4) With or Without Cetuximab in the 1st Line Treatment of Metastatic Colorectal Cancer (mCRC) in Chinese Rat Sarcoma Viral Oncogene Homolog (RAS) Wild-type Patients | — | Completed | — | — | — |
NCT01161316CT.gov Safety and Efficacy Study of mFOLFOX-6 Plus Cetuximab for 8 Cycles Followed by mFOLFOX-6 Plus Cetuximab or Single Agent Cetuximab as Maintenance Therapy in Patients With Metastatic Colorectal Cancer and WT KRAS Tumours | — | Completed | — | — | — |
NCT01167725CT.gov Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer | — | Terminated | — | — | — |
NCT01190462CT.gov Cetuximab and Simvastatin in Treating Patients With Advanced or Metastatic Colorectal Cancer | — | Unknown | — | — | — |
NCT01086267CT.gov Safety and Efficacy Study of BMS-908662 Alone or in Combination With Cetuximab in Subjects With K-RAS or B-RAF Mutation Positive Advanced or Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT01184482CT.gov Lapatinib and Cetuximab in Patients With Solid Tumors | — | Completed | — | — | — |
NCT01280643CT.gov Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer | — | Terminated | — | — | — |
NCT01060423CT.gov TACE With Irinotecan Drug-eluting Beads and Intravenous (IV) Cetuximab in Refractory Colorectal Cancer | — | Terminated | — | — | — |
NCT01075048CT.gov ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00803647CT.gov A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver | — | Completed | — | — | — |
NCT01032291CT.gov A Study to Assess the Efficacy and Safety of Lenalidomide in Combination With Cetuximab in Pre-treated Patients With KRAS Mutant Colorectal Cancer | — | Terminated | — | — | — |
NCT00908024CT.gov Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors | — | Terminated | — | — | — |
NCT00766220CT.gov Yttrium Microspheres With Cetuximab Plus Irinotecan for Patients With Advanced Colorectal Cancer Mets to Liver | — | Withdrawn | — | — | — |
NCT01008475CT.gov EMD 525797 in Combination With Cetuximab and Irinotecan in K-ras Wild Type Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT01030042CT.gov Trial Comparing Two Two Sequences of Therapy in Colorectal Metastatic Patients | — | Completed | — | — | — |
NCT01004159CT.gov Cetuximab Plus Irinotecan in Colorectal Cancer Patients Who Progressed After Failure With Cetuximab Plus Irinotecan | — | Terminated | — | — | — |
NCT00954876CT.gov Study of Capecitabine and Cetuximab as First-Line Therapy in Patients With Metastatic Wild Type Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Colorectal Cancer | — | Withdrawn | — | — | — |
NCT00975897CT.gov Study of Tumor Tissue Testing in Selecting Treatment for Patients With Metastatic or Locally Advanced Colorectal Cancer | — | Completed | — | — | — |
NCT00925015CT.gov Phase I Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Participants With Colorectal Cancer (MK-0646-016) | — | Completed | — | — | — |
NCT00931840CT.gov A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma | — | Unknown | — | — | — |
NCT01225744CT.gov Erbitux Study of CPT11, Oxaliplatin, UFToral Targeted Therapy | — | Completed | — | — | — |
NCT01068132CT.gov Prognostic Factors for Patients With Advanced Colorectal Cancer Treated With Cetuximab. | — | Completed | — | — | — |
NCT00686166CT.gov S0713: Oxaliplatin, Capecitabine, Cetuximab, and RT Followed By Surgery in Pts W/Stage II or III Rectal Cancer | — | Completed | — | — | — |
NCT01051167CT.gov Bi-weekly Cetuximab Combined With 5-fluorouracil/Leucovorin/Oxaliplatin (FOLFOX-6) in Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00778830CT.gov Study Evaluating the Safety and Efficacy of FOLFIRI Plus Cetuximab or FOLFOX Plus Cetuximab as First-line Therapy in Subjects With KRAS Wild-type Metastatic Colorectal Cancer (APEC-Study) | — | Completed | — | — | — |
NCT00719199CT.gov Study of FOLFIRI Plus Cetuximab Plus IMO-2055 in Patients With Colorectal Cancer | — | Terminated | — | — | — |
NCT00755534CT.gov Irinotecan/Cetuximab Followed by XELOX/Cetuximab vs the Reverse Sequence in Metastatic CRC | — | Terminated | — | — | — |
NCT00784667CT.gov Dual Inhibition of EGFR Signalling Using the Combination of Cetuximab and Erlotinib | — | Unknown | — | — | — |
NCT00755118CT.gov Lohp, 5-Fu/Lv and Bevacizumab, Alternative With Cpt-11, 5-Fu/Lv and Cetuximab In Metastatic Crc | — | Terminated | — | — | — |
NCT00852228CT.gov Optimal Control of Liver Metastases From Colorectal Cancer With Cetuximab and Hepatic Artery Infusion of Chemotherapy | — | Unknown | — | — | — |
NCT00743678CT.gov Neoadjuvant FOLFOX6 + Cetuximab in Patients With Colorectal Cancer and Unresectable Liver Metastasis | — | Completed | — | — | — |
NCT00640471CT.gov Cetuximab With or Without Brivanib in Treating Patients With K-Ras Wild Type Tumours and Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00594984CT.gov Phase I/II Combination With Irinotecan- Erbitux | — | Completed | — | — | — |
NCT00660582CT.gov FLOX + Cetuximab (Erbitux®) for Patients With Metastatic Colorectal Cancer and Wild Type K-RAS Tumor | — | Completed | — | — | — |
NCT00681876CT.gov Phase II Study of Avastin + Erbitux + Irinotecan as 2nd Line Treatment of Colorectal Cancer | — | Terminated | — | — | — |
NCT01310985CT.gov A Trial of Pre-Operative Chemoradiotherapy Using Capecitabine, Radiation & Cetuximab, in Rectal Cancer | — | Completed | — | — | — |
NCT00637091CT.gov Efficacy Analysis of Cetuximab Plus Irinotecan in Patients With Wild-type KRAS Without Regard to Epidermal Growth Factor Receptor (EGFR) Expressions | — | Completed | — | — | — |
NCT00598975CT.gov NKTR-102 in Combination With Cetuximab in Patients With Refractory Solid Tumors (Phase 2a) and Metastatic or Locally Advanced Colorectal Cancer (Phase 2b) | — | Completed | — | — | — |
NCT00479752CT.gov Safety and Efficacy of Folfox4 + Weekly Cetuximab vs Folfox 4+Biweekly Cetuximab by Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00614393CT.gov Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Metastatic Colorectal Cancer (MK-0646-004) | — | Completed | — | — | — |
NCT00577109CT.gov A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Previously Untreated Metastatic Colorectal Cancer. | — | Withdrawn | — | — | — |
NCT00551213CT.gov A Study to Determine the Activity of Robatumumab (SCH 717454, MK-7454) in Participants With Relapsed or Recurrent Colorectal Cancer (P04721, MK-7454-003) | — | Completed | — | — | — |
NCT00531115CT.gov Phase II Study to Evaluate Safety and Efficacy of Cetuximab in Combination With XELOX for 12 Weeks Followed by Maintenance Treatment With Cetuximab Plus Capecitabine as First-line Treatment in Elderly Patients With Metastatic Colorectal Cancer. | — | Terminated | — | — | — |
NCT01878422CT.gov Sequential Treatment Strategy for Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00593060CT.gov Temsirolimus (CCI-770, Torisel) Combined With Cetuximab in Cetuximab-Refractory Colorectal Cancer | — | Completed | — | — | — |
NCT00541112CT.gov Radiation Therapy, Chemotherapy, and Cetuximab Followed by Surgery, Chemotherapy, and Cetuximab in Treating Patients With Locally Advanced or Metastatic Rectal Cancer That Can Be Removed by Surgery | — | Terminated | — | — | — |
NCT00497497CT.gov A Study of PRO95780 in Combination With Cetuximab and Irinotecan Chemotherapy or the FOLFIRI Regimen With Bevacizumab in Patients With Previously Treated Metastatic Colorectal Cancer (APM4187g) | — | Completed | — | — | — |
NCT00309179CT.gov A Phase II Study of the Safety and Efficacy of E7820 Plus Cetuximab in Colorectal Cancer, Preceded by a Run-in Study in Advanced Solid Tumors | — | Completed | — | — | — |
NCT00557102CT.gov Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver and/or Lung | — | Completed | — | — | — |
NCT00522665CT.gov Phase I/Randomized Phase II Study of Second Line Therapy With Irinotecan + Cetuximab +/- RAD001 for Colorectal Cancer | — | Completed | — | — | — |
NCT00640081CT.gov Combination Chemotherapy and Cetuximab as First-Line Therapy in Treating Patients With Advanced and/or Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00689624CT.gov Irinotecan/Oxaliplatin/5-Fluorouracil/Leucovorin/Cetuximab As First Line Treatment In Colorectal Cancer | — | Completed | — | — | — |
NCT00513266CT.gov Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer With Liver Metastases or Lung Metastases That Are Potentially Removable by Surgery | — | Unknown | — | — | — |
NCT00503685CT.gov Study Using IMC-A12 (Cixutumumab) With or Without Cetuximab in Participants With Metastatic Colorectal Cancer Who Have Failed a Treatment Regimen That Consisted of a Prior Anti-EGFR Therapy | — | Completed | — | — | — |
NCT00537823CT.gov Pre- and Post-operative FOLFOX Based Therapy for Patients With Colorectal Cancer With Liver Involvement | — | Terminated | — | — | — |
NCT00478634CT.gov A Phase 1 Study Investigating the Combination of RAD001, Cetuximab and Irinotecan as Second-line Therapy After FOLFOX (or XELOX) Plus Bevacizumab in Patients With Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00766142CT.gov Chemotherapy and Cetuximab in Patients Undergoing Surgery for Peritoneal Carcinomatosis From Colorectal Cancer | — | Terminated | — | — | — |
NCT00501410CT.gov FOLFOX Chemotherapy Regimen (5-FU, Leucovorin, Oxaliplatin) in Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00437268CT.gov A Study of Irinotecan Plus Cetuximab With or Without Enzastaurin in Participants With Colorectal Cancer | — | Completed | — | — | — |
NCT00436072CT.gov ZD6474, Cetuximab, and Irinotecan in Patients With Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00482222CT.gov Combination Chemotherapy With or Without Cetuximab Before and After Surgery in Treating Patients With Resectable Liver Metastases Caused By Colorectal Cancer | — | Unknown | — | — | — |
NCT00422773CT.gov Safety of Cetuximab and Oxaliplatin/5-FU/FA/Irinotecan in First-Line Treatment of Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00438737CT.gov Cetuximab, Leucovorin, Oxaliplatin, and Fluorouracil With or Without Bevacizumab in Treating Patients With Resectable Liver Metastases From Colorectal Cancer | — | Unknown | — | — | — |
NCT00433927CT.gov 5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer (CRC) | — | Unknown | — | — | — |
NCT00544349CT.gov Leucovorin, Fluorouracil, Cetuximab, and Oxaliplatin in Treating Patients With Stage IV Colorectal Cancer and Liver Metastases That Cannot Be Removed by Surgery | — | Completed | — | — | — |
NCT00392470CT.gov Radiation Therapy, Irinotecan, and Cetuximab in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Rectal Cancer | — | Unknown | — | — | — |
NCT00671372CT.gov A Study of Dulanermin Administered in Combination With Camptosar®/Erbitux® Chemotherapy or FOLFIRI (With or Without Bevacizumab) in Subjects With Previously Treated Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00326495CT.gov BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer | — | Completed | — | — | — |
NCT00327093CT.gov Elaboration of a Model for Predicting Efficacy of Monoclonal Antibodies (Cetuximab and Bevacizumab) in Patients With Colorectal Cancer and Liver Metastases | — | Terminated | — | — | — |
NCT00251186CT.gov First-Line Capecitabine and Cetuximab for Metastatic Colorectal Ca in Elderly Patients | — | Terminated | — | — | — |
NCT00290615CT.gov Capecitabine, Cetuximab, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer That Cannot Be Removed By Surgery | — | Completed | — | — | — |
NCT00207051CT.gov BMS-582664 in Combination With Erbitux in Patients With Advanced Gastrointestinal Malignancies | — | Completed | — | — | — |
NCT00271011CT.gov A Study of Mitomycin C, Irinotecan, and Cetuximab | — | Terminated | — | — | — |
NCT00622674CT.gov Bortezomib and Cetuximab in Treating Patients With Advanced Solid Tumors | — | Completed | — | — | — |
NCT03362684CT.gov PETACC-8 miR-31-3p and miR-31-5p Ancillary Study | — | Completed | — | — | — |
NCT00265850CT.gov Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00265811CT.gov Combination Chemotherapy With or Without Cetuximab in Treating Patients With Stage III Colon Cancer That Was Completely Removed By Surgery | — | Completed | — | — | — |
NCT00559741CT.gov Cetuximab and Combination Chemotherapy in Treating Patients With Advanced or Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00383695CT.gov Oxaliplatin, Capecitabine, and Radiation Therapy With or Without Cetuximab in Treating Patients Undergoing Surgery for High-Risk Rectal Cancer | — | Unknown | — | — | — |
NCT00556413CT.gov Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00252564CT.gov Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00538291CT.gov Cetuximab and Capecitabine in Treating Patients With Metastatic Colorectal Cancer That Failed Irinotecan Treatment | — | Terminated | — | — | — |
NCT00286130CT.gov Safety and Efficacy of Folfox6 + Cetuximab Versus Folfiri +Cetuximab in Patients With Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00125034CT.gov Oxaliplatin and Cetuximab in First-line Treatment of Metastatic Colorectal Cancer (mCRC) | — | Completed | — | — | — |
NCT00208546CT.gov Cetuximab, Capecitabine, Oxaliplatin and Bevacizumab in Advanced Colorectal Cancer | — | Completed | — | — | — |
NCT00466505CT.gov Cetuximab & Celecoxib for Metastatic Colorectal Cancer or Colorectal Cancer That Cannot Be Removed by Surgery | — | Completed | — | — | — |
NCT00145314CT.gov FLOX in Combination With Cetuximab in First-line Treatment of Colorectal Cancer | — | Completed | — | — | — |
NCT00182715CT.gov Combination Chemotherapy With or Without Cetuximab as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer | — | Unknown | — | — | — |
NCT00202787CT.gov Safety and Efficacy Study of Combination Therapy With Cetuximab and FOLFOX4 in Patients With Colorectal Cancer | — | Completed | — | — | — |
NCT00056030CT.gov Combination Chemotherapy Plus Cetuximab in Treating Patients With Liver Metastases From Colorectal Cancer | — | Completed | — | — | — |
NCT00153998CT.gov Cetuximab in Neoadjuvant Treatment of Non-Resectable Colorectal Liver Metastases (CELIM) | — | Completed | — | — | — |
NCT00254137CT.gov Cap/Iri Plus Cetuximab Compared to Cap/ox Plus Cetuximab in Patients With Metastatic Colorectal Cancer. | — | Completed | — | — | — |
NCT00444678CT.gov Cetuximab Plus Biweekly Capecitabine and Oxaliplatin in KRAS Wild Type Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00226941CT.gov A Phase 1-2 Trial of Cetuximab in Combination With Oxaliplatin, Capecitabine, and Radiation Therapy Followed by Surgery for Locally-advanced Rectal Cancer | — | Terminated | — | — | — |
NCT00227734CT.gov Capecitabine and Oxaliplatin With or Without Cetuximab in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery | — | Completed | — | — | — |
NCT00820417CT.gov Pharmocokinetic/Pharmacodynamic (PK/PD) Study of the Combination Cetuximab/Gefitinib | — | Completed | — | — | — |
NCT00251485CT.gov A Phase II Trial of Modified FOLFOX 6 and Cetuximab in First Line Treatment of Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00084773CT.gov Neoadjuvant Cetuximab, Fluorouracil, and Pelvic Irradiation in Treating Patients With Locally Advanced or Locally Recurrent Rectal Cancer | — | Completed | — | — | — |
NCT00079066CT.gov Cetuximab + Best Supportive Care Compared With Best Supportive Care Alone in Metastatic Epidermal Growth Factor Receptor-Positive Colorectal Cancer | — | Completed | — | — | — |
NCT00207155CT.gov An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer | — | Completed | — | — | — |
NCT00077233CT.gov FOLFIRI or FOLFOX With or Without Cetuximab in Patients With Metastatic Adenocarcinoma of the Colon or Rectum | — | Terminated | — | — | — |
NCT00063141CT.gov Study of Irinotecan and Cetuximab Versus Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive Colorectal Cancer | — | Completed | — | — | — |
NCT00061815CT.gov Study of Cetuximab, Oxaliplatin, 5-FU/LV Versus Oxaliplatin, 5-FU/LV in Patients With Previously Treated Metastatic, EGFR-Positive Colorectal Cancer | — | Completed | — | — | — |
NCT00020930CT.gov Cetuximab in Treating Patients With Stage IV Colorectal Cancer | — | Completed | — | — | — |
NCT00020917CT.gov Cetuximab Plus Combination Chemotherapy in Treating Patients With Stage IV Colorectal Cancer | — | Completed | — | — | — |
NCT00005076CT.gov Cetuximab and Irinotecan in Treating Patients With Advanced Colorectal Cancer | — | Completed | — | — | — |
NCT00571740CT.gov Cetuximab and Bevacizumab as First-Line Therapy Followed By Combination Chemotherapy and Bevacizumab With or Without Cetuximab as Second-Line Therapy in Treating Patients With Stage IV Colorectal Cancer | — | Withdrawn | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Colorectal Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cetuximab (this asset) | Fudan University | Approved | BB · 67 |
| Desflurane | Peter MacCallum Cancer Centre, Australia | P4 | BBB |
| Marble Dust | James Varani | P2/3 | BB |
| Oxaliplatin | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | P4 | BB |
| Orectalip | Sinphar Pharmaceutical Co., Ltd | P4 | BB |
| Fluorouracilum | UNICANCER | P4 | BB |
| Levofolinic Acid | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | P3 | BB |
| Fentanyl | Mansoura University | P4 | BB |
| Panitumumab | MSPU des 3 Provinces | P3 | BB |
+42 more in the Colorectal Cancer cohort
Other indications for Cetuximab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Colon Adenocarcinoma | — | P3 | BB · 70 |
| Rectal Carcinoma | — | P2 | BB · 69 |
| Non-Small Cell Lung Carcinoma | — | P3 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Cetuximab in Colorectal Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cetuximab-colorectal-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →